MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company also has a translational research agreement with NanoString Technologies, Inc. for the identification and development of biomarkers for MGD013 program. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone301-251-5172
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$157.74 million
Profitability
Miscellaneous
Employees330
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.17. The biopharmaceutical company had revenue of $18.83 million for the quarter, compared to analysts' expectations of $4.41 million. MacroGenics had a negative return on equity of 7.39% and a negative net margin of 10.72%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
11 analysts have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $33.20 in the next twelve months. This suggests a possible upside of 49.9% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $39 (raised from $34) price target for shares of MacroGenics is based on a 13-year DCF-driven sum-of-the-parts analysis and in light of the recent clinical update, we have raised the POS of an anticipated treatment duration of 6 months. Our DCF is driven by: beta of 1.73, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.4%, and tax rate of 15% beginning in FY 2027. (19%), flotetuzumab (17%) together represent about 99% of our target." (2/6/2019)
- 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (11/13/2018)
- 3. Cowen Inc analysts commented, "We hosted SAGE’s CFO Kimi Iguchi and CMO Steve Kanes at our 2018 Boston, MA. While our discussion touched upon several topics, the most important takeaway in our view was that management appears very confident heading into the 4Q18 availability of top-line pivotal trial data on SAGE-217 in postpartum depression (PPD). We believe this is a key stock driver as these data have a read-through for the development of SAGE-217 in major depressive disorder (MDD), which is a significantly larger indication vs. PPD (see here). Recall that SAGE-217 is an oral, small-molecule product with a novel mechanism of action. If approved, SAGE-217 could change the treatment paradigm from the current standard of care that relies on chronic treatment of MDD to an episodic one." (8/8/2018)
Has MacroGenics been receiving favorable news coverage?
Media stories about MGNX stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Mirati Therapeutics (MRTX) and Arena Pharmaceuticals (ARNA).
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 67)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.05%), BB Biotech AG (7.77%), Bellevue Group AG (2.52%), Dimensional Fund Advisors LP (1.91%), Candriam Luxembourg S.C.A. (1.28%) and Rhenman & Partners Asset Management AB (1.28%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.
Which major investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Pinnacle Associates Ltd., MetLife Investment Advisors LLC, New York State Common Retirement Fund, United Services Automobile Association and Victory Capital Management Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.
Which major investors are buying MacroGenics stock?
MGNX stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, BB Biotech AG, Dimensional Fund Advisors LP, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., BlackRock Inc., 361 Capital LLC and Opaleye Management Inc.. View Insider Buying and Selling for MacroGenics.
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $22.15.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $936.04 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
